Biotricity (BTCY) Q1 2027 earnings summary

Executive summary

• Revenue for the quarter ended June 30, 2026, grew 10.4% year-over-year to $4.3 million, driven by a 23.6% increase in recurring technology fee revenue, offsetting a decline in device sales.

• Gross margin improved to 82.6% from 80.5% year-over-year, reflecting higher margins on technology fees and device sales.

• Operating income declined 43.9% to $0.16 million due to a 26.2% increase in selling, general, and administrative expenses, mainly from higher share-based compensation.

• Net loss widened to $0.96 million from $0.67 million in the prior-year quarter, with EBITDA of $90,000, down from $0.33 million, impacted by one-time share-based compensation charges.

• This marks the third consecutive quarter of positive profit from operations before capital costs.

Financial highlights

• Technology fee revenue reached $4.2 million, up 23.6% year-over-year, comprising 97.4% of total revenue.

• Device sales declined, making up only 2.6% of total revenue.

• Gross profit was $3.53 million, with a gross margin of 82.6%.

• Operating expenses rose to $3.37 million, mainly due to increased share-based compensation.

• Interest expense remained stable at $0.85 million.

Outlook and guidance

• Management anticipates continued revenue growth and margin expansion, supported by strong customer retention and increased recurring revenue.

• The company expects to improve liquidity through business development and additional equity and debt capitalization.

• Ongoing investment in R&D and commercialization of new products is planned, with a focus on expanding AI-driven cardiac care solutions.